Dose Insider / Glossary / Half-life

Half-lifeWhat it means and how long each GLP-1 lasts

Updated November 20, 2026 · 4 min read · FDA and DailyMed labels of 7 medicines, 2025-2026

The half-life of a medicine is the time it takes for its level in the blood to fall by half. For GLP-1 medicines it decides how often they are taken: semaglutide, with a half-life of about 1 week, is injected weekly, while liraglutide, at 13 hours, is injected daily. It also explains how long a medicine lingers after the last dose, which matters for side effects, surgery and pregnancy planning.1,2

about 7 daysSemaglutide, half-life in the blood
Half-life in the bloodDays, from each labelSemaglutideabout 7 daysTirzepatideabout 5 daysDulaglutideabout 5 daysOrforglipron29 to 49 hoursLiraglutide13 hoursHalf-life in the bloodDays, from each labelSemaglutideabout 7 daysTirzepatideabout 5 daysDulaglutideabout 5 daysOrforglipron29 to 49 hoursLiraglutide13 hours

The body's own GLP-1 lasts only 1.5 to 2 minutes.

On this page

The half-life of each medicine

MoleculeBrandsHalf-lifeTaken
SemaglutideOzempic, Wegovy, RybelsusAbout 1 weekWeekly shot or daily tablet
TirzepatideMounjaro, ZepboundAbout 5 daysWeekly shot
DulaglutideTrulicityAbout 5 daysWeekly shot
OrforglipronFoundayo29 to 49 hoursDaily tablet
LiraglutideVictoza, SaxendaAbout 13 hoursDaily shot
ExenatideByetta2.4 hoursTwice a day

Section 12.3 of each label.1,2,3,4,5,6

In days, that is about 7 for semaglutide, 5 for tirzepatide and dulaglutide, about 1 to 2 for orforglipron and about 0.5 for liraglutide. The body's own GLP-1 is in a different league: the Saxenda label puts its half-life at 1.5 to 2 minutes, because enzymes break it down almost at once.2 Every GLP-1 medicine is, in effect, a way to make that hormone last longer. Semaglutide and liraglutide do it by binding to albumin, the main protein in blood, and dulaglutide by being fused to a fragment of an antibody.1,4

How the level builds up

A weekly dose does not reach its full effect on the first day. Each new dose adds to what is left of the previous ones until intake and clearance balance out, which is called steady state. The Ozempic label says steady state is reached after 4 to 5 weeks of weekly doses, and the Mounjaro label after 4 weeks.1,3 That is one reason the dose climbs in steps of at least 4 weeks: each step gets time to settle.

Within a week the level also rises and falls. After a semaglutide injection the peak comes 1 to 3 days later; after tirzepatide, 8 to 72 hours later.1,3 Some people notice side effects such as nausea most in the days after a shot, which fits that timing. Our page on timing a weekly GLP-1 shot draws the curve.

After the last dose

A long half-life means a slow exit. The Ozempic label says that with a half-life of about 1 week, semaglutide stays in the circulation for about 5 weeks after the last dose.1 Because of that long half-life, the Wegovy label advises stopping it at least 2 months before a planned pregnancy.7

The same logic applies to switching. Moving from one weekly medicine to another does not start from zero, because the first is still fading when the second begins. Our page on switching from Wegovy to Zepbound shows how the labels handle the overlap.

Before surgery or sedation

A medicine that lingers also keeps working on the stomach. The Zepbound label notes that tirzepatide delays stomach emptying and that there have been rare reports of pulmonary aspiration, food from the stomach entering the lungs, in people on GLP-1 medicines who had general anesthesia or deep sedation. Some of them still had food in the stomach despite following the usual fasting rules. The label says the available data are not enough to recommend how to lower that risk, and it asks patients to tell their care team about any planned surgery or procedure.8 Our page on how long Zepbound stays in your system shows the fade after a last dose.

Half-life and missed doses

The missed-dose windows on the labels follow the half-lives. Semaglutide, the longest-lasting, allows a missed Ozempic shot within 5 days; tirzepatide allows 4 days; the daily tablets, with much shorter half-lives, simply move on to the next day.1,3,5 Our page on missed doses works through the calendar.

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 2.1 and 12.3. accessdata.fda.gov
  2. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; sections 12.1 and 12.3. dailymed.nlm.nih.gov
  3. MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 2 and 12.3. accessdata.fda.gov
  4. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; sections 11 and 12.3. dailymed.nlm.nih.gov
  5. FOUNDAYO (orforglipron) tablets prescribing information, Eli Lilly and Company, DailyMed version published August 13, 2026, sections 2 and 12.3; and RYBELSUS and OZEMPIC tablets prescribing information, revised January 2026, section 2. dailymed.nlm.nih.gov
  6. BYETTA (exenatide) injection prescribing information. AstraZeneca; DailyMed, version published September 8, 2025; section 12.3. dailymed.nlm.nih.gov
  7. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 8.3. accessdata.fda.gov
  8. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 5. accessdata.fda.gov

Related analyses

Log each dose and see your estimated level rise and fall between them.

Open Dose Insider